Biochemical correlation of serum insulin, high-sensitivity C reactive protein and lipid tetrad index with thyroid-stimulating hormone levels in patients with hypothyroidism

Mandayal Jamatia; Avdhesh Kumar Sharma; Rimpy Charak

doi:10.18203/2320-6012.ijrms20262625

Authors

Mandayal Jamatia Department of Biochemistry, Jaipur National University Institute of Medical Sciences and Research Centre, Jaipur, Rajasthan, India
Avdhesh Kumar Sharma Department of Medical Biochemistry, Index Medical College Hospital and Research Centre, Indore, Madhya Pradesh, India
Rimpy Charak Department of Biochemistry, Jaipur National University Institute of Medical Sciences and Research Centre, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20262625

Keywords:

Cardiovascular risk, Lipid tetrad index, High-sensitivity C-reactive protein, HOMA-IR, Hypothyroidism, Thyroid-stimulating hormone, Insulin resistance

Abstract

Background: Hypothyroidism is a prevalent endocrine disorder associated with insulin resistance, dyslipidemia, chronic low-grade inflammation, and an increased risk of cardiovascular disease. Thyroid hormone deficiency adversely affects glucose and lipid metabolism, contributing to metabolic dysfunction. This study investigated the relationship between thyroid-stimulating hormone (TSH) levels and markers of insulin resistance, systemic inflammation, and atherogenic risk in patients with hypothyroidism.

Methods: A hospital-based cross-sectional analytical study was conducted among 70 patients with hypothyroidism attending a tertiary care teaching hospital in Indore, Madhya Pradesh, India. Based on thyroid function tests, participants were categorized as having overt or subclinical hypothyroidism. Serum triiodothyronine (T3), thyroxine (T4), TSH, fasting insulin, high-sensitivity C-reactive protein (hs-CRP), and lipid profile were measured using standard laboratory methods. Insulin resistance was assessed using the homeostatic model assessment for insulin resistance (HOMA-IR), while atherogenic risk was evaluated using the lipid tetrad index (LTI). Correlation analysis was performed to examine associations between TSH and study variables.

Results: Serum TSH demonstrated significant positive correlations with fasting insulin (r=0.42, p<0.01), hs-CRP (r=0.38, p<0.01), and LTI (r=0.44, p<0.001). Compared with patients with subclinical hypothyroidism, those with overt hypothyroidism had significantly higher fasting insulin, HOMA-IR, hs-CRP, and LTI values. Insulin resistance was identified in 58.6% of participants.

Conclusions: Higher TSH levels are associated with insulin resistance, systemic inflammation, and increased atherogenic risk in hypothyroidism. These findings highlight the importance of comprehensive metabolic assessment for improved cardiovascular risk stratification and timely clinical intervention.

References

Vanderpump MPJ. Epidemiology of thyroid disease. Br Med Bull. 2011;99:39-51.

Brenta G. Why is insulin resistance a natural consequence of thyroid dysfunction? J Thyroid Res. 2011;2011:152850.

Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on the lipid profile. Open Cardiovasc Med J. 2011;5:76-84.

Pearson TA, Mensah GA, Alexander RW, Jeffrey LA, Richard OC 3rd, Michael C, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practices. Circulation. 2003;107(3):499-511.

Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010;1(2):36-47.

Hollowell JG, Staehling NW, Flanders WD, W Harry H, Elaine WG, Carole AS, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988-1994): NHANES III. J Clin Endocrinol Metab. 2002;87(2):489-99.

Carle A, Laurberg P, Knudsen N, Peter L, Anne K, Lars O, et al. Thyroid function and body weight: a community-based longitudinal study. Endocrine. 2015;49(1):8-16.

Dominguez LJ, Barbagallo M. Hypothyroidism and cardiovascular risk: mechanisms and prevention. Endocr Metab Immune Disord Drug Targets. 2008;8(4):271-7.

Khandelwal D, Tandon N. Overt and subclinical hypothyroidism: who to treat and how? Drugs. 2012;72(1):17-33.

Zimmermann MB. Iodine deficiency. Endocr Rev. 2009;30(4):376-408.

Kalra S, Unnikrishnan AG, Sahay R. Thyroid disorders in India: An epidemiological perspective. Thyroid Res Pract. 2013;10(1):11-4.

Engler H, Riesen WF. Effect of thyroid dysfunction on lipoprotein(a). Clin Chim Acta. 1993;214(1):59-66.

McCormick SP. Lipoprotein(a): biology and clinical importance. Clin Biochem Rev. 2004;25(1):69-80.

Ridker PM. C-reactive protein and cardiovascular risk. Circulation. 2009;119(21):e442-5.

Myers GL, Rifai N, Tracy RP. CDC/AHA workshop on markers of inflammation and cardiovascular disease. Clin Chem. 2004;50(1):21-4.

Taddei S, Caraccio N, Virdis A, Angela D, Daniele V, Lorenzo G, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism. J Clin Endocrinol Metab. 2006;91(12):5076-82.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Diabetologia. 1985;28(7):412-9.

Sayed AL, Sany D. Insulin resistance in subclinical hypothyroidism. Endocr Pract. 2006;12(5):570-5.

Tuzcu A, Bahceci M, Gokalp D, Yekta T, Kemal G. Subclinical hypothyroidism may be associated with elevated HOMA levels. Endocr J. 2005;52(1):89-93.

Enas EA, Chacko V, Senthilkumar A. Lipid Tetrad Index and CAD in Asian Indians. Indian Heart J. 1997;49(4):395-404.

Das B, Daga MK, Gupta SK. Lipid tetrad index in cardiovascular disease. J Assoc Physicians India. 2007;55:735-8.

McLachlan SM, Rapoport B. Thyroid peroxidase as an autoantigen. Thyroid. 1992;2(3):201-6.

Mariotti S, Caturegli P, Piccolo P, Barbesino G, Pinchera A. Thyroid autoantibodies in thyroid diseases. Clin Endocrinol (Oxf). 1990;33(6):639-46.

Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142-54.

Chiovato L, Latrofa F, Braverman LE, Furio P, Marco C, Lucio M, et al. Disappearance of humoral thyroid autoimmunity. J Clin Endocrinol Metab. 2003;88(2):693-9.

Guo J, Rapoport B, McLachlan SM. Thyroid peroxidase antibody activates complement. Endocrinology. 1997;138(2):756-61.

Rabiee A. Anti-thyroid peroxidase antibodies in autoimmune thyroiditis. Autoimmun Rev. 2021;20(7):102851.

Grüters A, Krude H. Detection and treatment of congenital hypothyroidism. Nat Rev Endocrinol. 2011;8(2):104-13.

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States. JAMA. 2006;295(18):2164-7.

Horton R. Global Burden of Endocrine Disorders. Lancet. 2010;376(9750):1521-2.

Inoue K, Tsujimoto T, Saito J, Ramin E, Connie MR, Angela ML, et al. Association of subclinical hypothyroidism and cardiovascular disease with mortality. JAMA Netw Open. 2020;3(2):e1920745.

Ettleson MD, Bianco AC. Cardiovascular outcomes in subclinical thyroid disease. Eur Thyroid J. 2023;12(5):e230067.

Dell’Aquila M. Subclinical hypothyroidism and clinical outcomes after cardiovascular interventions. Clin Cardiol. 2024;47(3):215-23.

Wang P, Weiming Z, Haiyan L. Research status of subclinical hypothyroidism in promoting cardiovascular disease. Front Cardiovasc Med. 2025;12:1527271.

Zhong L, Tong X, Jifeng L, Huahui Z, et al. Metabolic syndrome and risk of subclinical hypothyroidism: a systematic review and meta-analysis. Front Endocrinol. 2024;15:1399236.

Isailă OM, Alin-Ionut P, Sorin H. The relationship between subclinical hypothyroidism and cardiovascular disease. J Cardiovasc Dev Dis. 2024;11(4):98.

Gosi SKY, Jasleen K, Vishnu VG. Subclinical Hypothyroidism. StatPearls Publishing, 2024.

Han F, Guo H, Zhang H, Yang Z. hs-CRP/HDL-C can predict mortality risk in cardiovascular-kidney-metabolic syndrome. Front Endocrinol. 2025;16:1552219.

Biondi B. Subclinical hypothyroidism in patients with obesity and metabolic syndrome. Nutrients. 2023;16(1):87.

Safari F, Ali N, Hossein MV. Association between thyroid function and insulin resistance in adults. BMC Endocr Disord. 2024;24(1):1779.